Literature DB >> 1971321

Evidence suggesting hyperoxaluria as a cause of nephrocalcinosis in phosphate-treated hypophosphataemic rickets.

G S Reusz1, K Latta, P F Hoyer, D J Byrd, J H Ehrich, J Brodehl.   

Abstract

Urinary excretion of oxalate and phosphate was measured in twelve vitamin-D-treated, phosphate-supplemented patients with X-linked hypophosphataemia (XLH; four children, eight adolescents and adults) to investigate possible causative factors of nephrocalcinosis other than calcium. Oxalate excretion correlated highly with urinary phosphate excretion and with intake of phosphate supplements corrected for body surface area. Young children received the highest relative doses of phosphate (range 2.27-10.8 g/1.73 m2 daily) and their urinary oxalate excretion was very high (0.94-3.38 mmol/1.73 m2 daily). The urinary oxalate excretion of untreated adults with XLH was within normal limits. Six patients had evidence of nephrocalcinosis on ultrasound. The high urinary oxalate excretion in phosphate-supplemented XLH may be seen as a special type of enteric hyperoxaluria, in which the conditions of calcium-oxalate crystal precipitation could be reached even at normal levels of urinary calcium excretion. Urinary excretion of both calcium and oxalate should therefore be monitored during treatment in young XLH patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971321     DOI: 10.1016/0140-6736(90)91304-s

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  14 in total

Review 1.  Evaluation of urinary tract calculi in children.

Authors:  S A Hulton
Journal:  Arch Dis Child       Date:  2001-04       Impact factor: 3.791

2.  More evidence for hyperoxaluria in phosphate-treated X-linked familial hypophosphataemic rickets.

Authors:  E Schönaue; K Kruse; H J Böhles; A C Sewell
Journal:  Eur J Pediatr       Date:  1992-05       Impact factor: 3.183

3.  X linked hypophosphataemia: treatment, height gain, and nephrocalcinosis.

Authors:  G S Reusz; P F Hoyer; M Lucas; H P Krohn; J H Ehrich; J Brodehl
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

Review 4.  Role of prostaglandins in the pathogenesis of X-linked hypophosphatemia.

Authors:  Michel Baum; Ashu Syal; Raymond Quigley; Mouin Seikaly
Journal:  Pediatr Nephrol       Date:  2006-05-24       Impact factor: 3.714

5.  Hypophosphatemic rickets: results of a long-term follow-up.

Authors:  Maria Helena Vaisbich; Vera H Koch
Journal:  Pediatr Nephrol       Date:  2005-10-27       Impact factor: 3.714

6.  Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets.

Authors:  Miroslav Zivičnjak; Dirk Schnabel; Heiko Billing; Hagen Staude; Guido Filler; Uwe Querfeld; Marius Schumacher; Anke Pyper; Carmen Schröder; Jürgen Brämswig; Dieter Haffner
Journal:  Pediatr Nephrol       Date:  2010-12-01       Impact factor: 3.714

Review 7.  Management of primary hyperoxaluria: efficacy of oral citrate administration.

Authors:  E Leumann; B Hoppe; T Neuhaus
Journal:  Pediatr Nephrol       Date:  1993-04       Impact factor: 3.714

8.  Causes of increased renal medullary echogenicity in Turkish children.

Authors:  A Nayir; A Kadioğlu; A Sirin; S Emre; E Tonguç; I Bilge
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

9.  Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease.

Authors:  A Taylor; N H Sherman; M E Norman
Journal:  Pediatr Nephrol       Date:  1995-04       Impact factor: 3.714

Review 10.  Therapeutics of X-linked hypophosphatemic rickets.

Authors:  K Latta; S Hisano; J C Chan
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.